BioTech IP Review

Assignee: Adicet Bio, Inc.
Patent Number: 11,299,708 B2
Priority (Filing) Date: May 12, 2016
Issued: April 12, 2022 (in force through 2025 and likely beyond)
Title: Methods for Selective Expansion of γδ T‑Cell Populations and Compositions Thereof

What This Patent Covers

This patent safeguards methods and compositions for producing enriched populations of γδ (gamma‑delta) T cells — a specific subset of white blood cells with unique anti‑tumor and immune‑modulating properties — and is highly relevant to Adicet’s “off‑the‑shelf” allogeneic T‑cell therapy programs.

Key aspects include:

• Selective expansion methods: Processes for ex vivo activation and multiplication of γδ T cells from mixed cell populations, which can generate clinically relevant numbers of these cells for therapeutic use.
• Engineered and non‑engineered cells: The technology supports expansion of both naturally occurring and genetically engineered γδ T cells (e.g., expressing chimeric antigen receptors, CARs).
• Compositions & therapeutic use: The enriched cells can be formulated into pharmaceutical compositions intended for adoptive cell therapy to treat cancers and immune disorders, and potentially administered as “off‑the‑shelf” treatments.

Crucially, this patent’s teachings underpin Adicet’s lead drug candidate ADI‑001, a CAR‑modified allogeneic γδ T‑cell therapy targeting CD20 for autoimmune diseases and cancer, which is in Phase 1 development as of 2025.

---

Why This Patent Is Important

• Platform foundational IP: It protects core technology on how to generate therapeutic γδ T‑cell products, which is Adicet’s unique platform for “off‑the‑shelf” cell therapies against autoimmune diseases and cancer.
• Commercial relevance: Adicet’s lead candidates, such as ADI‑001, rely on methods for producing and expanding these cell populations for clinical use, making this patent strategically critical even if it issued earlier.
• Long‑term exclusivity: Patent protection that remains effective through 2025 and beyond helps secure the company’s competitive position in the emerging allogeneic CAR‑T space.
• Technology leverage: Broader compositions and ex vivo methods covered by the patent could extend to future engineered cell therapies beyond current indications.